Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study / Sarzi-Puttini, P.; Filippucci, E.; Adami, S.; Meroni, P. L.; Batticciotto, A.; Idolazzi, L.; De Lucia, O.; Talavera, P.; Kumke, T.; Grassi, W.. - In: ADVANCES IN THERAPY. - ISSN 0741-238X. - 35:8(2018), pp. 1153-1168. [10.1007/s12325-018-0751-8]
Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study
Filippucci E.;Grassi W.
2018-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
